Vaccines Today—January 30, 2026

LucidQuest

3 days ago

This week’s Vaccines update in the summarizes the latest advancements including clinical trial progress, regulatory approvals, and strategic partnerships.

In Today’s Newsletter

Dive deeper

🦠 Immuno Cure’s HIV Vaccine Clinical Trial [26 Jan 2026]

https://macaubusiness.com/immuno-cure-kicks-off-phase-i-clinical-study-of-therapeutic-dna-vaccine-for-hiv-in-hong-kong/
Context: This vaccine aims for immune-mediated control of HIV-1 without the need for antiretroviral therapy.
Key point: Immuno Cure begins a Phase 1 trial for its HIV therapeutic DNA vaccine, ICVAX, in Hong Kong.
Implication: The study will explore optimal delivery methods, with funding support from Hong Kong’s Innovation and Technology Fund.

💉 Scancell’s iSCIB1+ in Advanced Melanoma [26 Jan 2026]

https://scancell.co.uk/wp-content/uploads/2026/01/20260126-iSCIB1-IND-clearance-Final.pdf
Context: This follows promising Phase 2 results showing significant improvement in progression-free survival.
Key point: The FDA clears Scancell’s iSCIB1+ for Phase 3 trial in advanced melanoma.
Implication: iSCIB1+ could redefine the standard of care for melanoma, showing potential to improve survival rates over current treatments.

🦠 GSK’s Arexvy RSV Vaccine Approval [26 Jan 2026]

https://www.biopharminternational.com/view/gsk-s-arexvy-gains-eu-approval-for-adults-aged-18-years-and-older
Context: This expands the vaccine’s use, previously approved for adults 60+ and high-risk 50-59 year olds.
Key point: Arexvy is now approved for all adults aged 18+ in the EU to prevent RSV.
Implication: It supports broader immunization strategies in adults, potentially reducing RSV-related hospitalizations.

🧬 Anixa’s Breast Cancer Vaccine Patent in Mexico [27 Jan 2026]

https://www.ad-hoc-news.de/boerse/news/ueberblick/anixa-biosciences-secures-key-mexican-patent-for-breast-cancer-vaccine/68527690
Context: This vaccine targets a protein re-expressed in breast cancer, showing promising early-phase trial results.
Key point: Anixa secures its first Mexican patent for its α-Lactalbumin-based breast cancer vaccine.
Implication: The patent boosts Anixa’s international IP portfolio, positioning it for global commercialization.

💰 SK Biosciences’ Ebola Vaccine Partnership [28 Jan 2026]

https://www.bioprocessintl.com/therapeutic-class/sk-biosciences-secures-30m-partnership-to-improve-ebola-vaccine-manufacturing
Context: The collaboration will enhance the vaccine’s yield and resilience, eliminating the need for cold storage.
Key point: SK biosciences secures a $30M grant from CEPI to improve Zaire ebolavirus vaccine manufacturing.
Implication: This partnership aims to make the vaccine more accessible in low-resource areas, improving global health preparedness.

🦠 SK Biosciences Initiates Universal COVID Vaccine Trial [29 Jan 2026]

https://www.prnewswire.com/apac/news-releases/sk-bioscience-initiates-international-phase-12-clinical-trial-of-universal-vaccine-candidate-targeting-sarbecovirus-family-302673365.html
Context: The vaccine aims to provide broad protection against coronaviruses, including future SARS-like strains.
Key point: SK biosciences begins a Phase 1/2 trial of GBP511, a universal vaccine targeting the Sarbecovirus family.
Implication: This is the first universal sarbecovirus vaccine to enter clinical trials, marking a significant step in pandemic preparedness.

Why it matters

Therapeutic and cancer vaccines are advancing into later-stage trials, signaling growing confidence in immune-based disease control beyond prevention.
Regulatory approvals and global partnerships are accelerating adult and pandemic-focused immunization strategies.
Platform innovations such as DNA vaccines and universal coronavirus targets are reshaping long-term vaccine competitiveness.
Manufacturing resilience and cold-chain–independent solutions are becoming critical enablers of global vaccine access and preparedness.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Vaccines archive on our research hub page.

FAQ

What is the significance of Immuno Cure’s HIV vaccine trial?

Immuno Cure’s trial could provide a novel therapeutic approach to HIV, reducing reliance on daily antiretroviral therapy and improving patient quality of life.

How does Scancell’s iSCIB1+ improve melanoma treatment?

Scancell’s iSCIB1+ has shown promising results in Phase 2 trials, with improved progression-free survival compared to the current standard of care. This could represent a breakthrough in melanoma immunotherapy.

Why is GSK’s RSV vaccine a game-changer?

By expanding its approval to all adults, GSK’s Arexvy could significantly reduce RSV-related hospitalizations and healthcare costs in adults, a growing concern in public health.

What does Anixa’s patent mean for its breast cancer vaccine?

Anixa’s Mexican patent strengthens its position in the breast cancer vaccine market, enhancing its ability to secure partnerships and funding for future clinical trials.

Entities / Keywords

Immuno Cure, HIV, DNA Vaccine, Scancell, Melanoma, iSCIB1+, GSK, Arexvy, RSV, Anixa, Breast Cancer, α‑Lactalbumin, SK Biosciences, Ebola, Universal Vaccine, Sarbecovirus, CEPI.